Press Release

**Cipla announces Q2 FY1415 Unaudited Consolidated Financial Results**

**Mumbai, India, 13th Nov 2014:** Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its Unaudited Consolidated Financial Results for the quarter ended September 30, 2014 (Q2).

**Key Financial & Performance Highlights Q2 FY1415 vis-a-vis Q2 FY1314:**
(Current year figures include the relevant results of Cipla’s subsidiaries from the date they became subsidiary of the company and therefore the corresponding figures for the previous period are not comparable).

- Net Sales grew by 5.9% to ₹2630 cr, up from ₹2484 cr
- Income from operations grew by 9.3% to ₹2767 cr, up from ₹2533 cr
- EBITDA at ₹558 cr, as against ₹567 cr for previous year
- Profit after tax at ₹299 cr, as against ₹358 cr for previous year
Profit & Loss Highlights:

- Material cost is at 36.7% of income from operations in Q2 FY1415 as compared to 37.7% in Q2 FY1314
- EBIDTA decreased by 1.5% in Q2 FY1415 as compared to Q2 FY1314 and is at 20.2% of income from operations during Q2 FY1415
- Profit after tax decreased by 16.6% to ₹299 cr during Q2 FY1415 as compared to ₹358 cr during Q2 FY1314

Performance Review:

Domestic business:

- Domestic sales grew by 20.5% to ₹1251 cr during Q2 FY1415, up from ₹1039 cr during Q2 FY1314
- The growth in domestic sales was largely on account of growth in Pediatrics, Respiratory, Spectracare and Urology therapies

International business:

- Exports of formulations grew by 0.4% to ₹1243 cr during Q2 FY1415, up from ₹1239 cr during Q2 FY1314.
- Exports of APIs declined to ₹136 cr during Q2 FY1415, from ₹206 cr during Q2 FY1314.

About Cipla:
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Our portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally. Cipla’s turnover in FY 14 was 1.67 billion USD.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla’s research and development focuses on developing innovative products and drug delivery systems and has given India and the world many ‘firsts’ for instance Triomune. In a tightly regulated environment, the company’s manufacturing facilities have approvals from all the main regulators including USFDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard of quality both domestically and internationally.

Media Contacts:

**Investor Relations**
Anant Atal  
Contact No.: 022 – 24826450  
E-Mail: anant.atal@cipla.com

**Corporate Communications**
Jaisingh Balakrishnan  
Contact No.: +91 9833836185  
E-Mail: jaisingh.krishnan@cipla.com